JP2019509737A - ＴＧＦβ１結合性免疫グロブリンおよびその使用 - Google Patents

ＴＧＦβ１結合性免疫グロブリンおよびその使用 Download PDF

Info

Publication number
JP2019509737A
JP2019509737A JP2018547346A JP2018547346A JP2019509737A JP 2019509737 A JP2019509737 A JP 2019509737A JP 2018547346 A JP2018547346 A JP 2018547346A JP 2018547346 A JP2018547346 A JP 2018547346A JP 2019509737 A JP2019509737 A JP 2019509737A
Authority
JP
Japan
Prior art keywords
antibody
tgfβ1
antigen
complex
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018547346A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509737A5 (cg-RX-API-DMAC7.html
Inventor
トーマス シュルフ，
トーマス シュルフ，
グレゴリー ジェイ． カルヴェン，
グレゴリー ジェイ． カルヴェン，
アビシェク ダッタ，
アビシェク ダッタ，
キンバリー ロング，
キンバリー ロング，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scholar Rock Inc
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58503696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2019509737(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of JP2019509737A publication Critical patent/JP2019509737A/ja
Publication of JP2019509737A5 publication Critical patent/JP2019509737A5/ja
Priority to JP2021174552A priority Critical patent/JP2022028680A/ja
Priority to JP2021209374A priority patent/JP2022031403A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018547346A 2016-03-11 2017-03-10 ＴＧＦβ１結合性免疫グロブリンおよびその使用 Withdrawn JP2019509737A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021174552A JP2022028680A (ja) 2016-03-11 2021-10-26 ＴＧＦβ１結合性免疫グロブリンおよびその使用
JP2021209374A JP2022031403A (ja) 2016-03-11 2021-12-23 ＴＧＦβ１結合性免疫グロブリンおよびその使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662307353P 2016-03-11 2016-03-11
US62/307,353 2016-03-11
US201762443615P 2017-01-06 2017-01-06
US62/443,615 2017-01-06
US201762452866P 2017-01-31 2017-01-31
US62/452,866 2017-01-31
PCT/US2017/021972 WO2017156500A1 (en) 2016-03-11 2017-03-10 Tgfb1-binding immunoglobulins and use thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2021174552A Division JP2022028680A (ja) 2016-03-11 2021-10-26 ＴＧＦβ１結合性免疫グロブリンおよびその使用
JP2021209374A Division JP2022031403A (ja) 2016-03-11 2021-12-23 ＴＧＦβ１結合性免疫グロブリンおよびその使用

Publications (2)

Publication Number Publication Date
JP2019509737A true JP2019509737A (ja) 2019-04-11
JP2019509737A5 JP2019509737A5 (cg-RX-API-DMAC7.html) 2020-04-16

Family

ID=58503696

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018547346A Withdrawn JP2019509737A (ja) 2016-03-11 2017-03-10 ＴＧＦβ１結合性免疫グロブリンおよびその使用
JP2021174552A Withdrawn JP2022028680A (ja) 2016-03-11 2021-10-26 ＴＧＦβ１結合性免疫グロブリンおよびその使用
JP2021209374A Pending JP2022031403A (ja) 2016-03-11 2021-12-23 ＴＧＦβ１結合性免疫グロブリンおよびその使用
JP2023100034A Pending JP2023108057A (ja) 2016-03-11 2023-06-19 ＴＧＦβ１結合性免疫グロブリンおよびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021174552A Withdrawn JP2022028680A (ja) 2016-03-11 2021-10-26 ＴＧＦβ１結合性免疫グロブリンおよびその使用
JP2021209374A Pending JP2022031403A (ja) 2016-03-11 2021-12-23 ＴＧＦβ１結合性免疫グロブリンおよびその使用
JP2023100034A Pending JP2023108057A (ja) 2016-03-11 2023-06-19 ＴＧＦβ１結合性免疫グロブリンおよびその使用

Country Status (19)

Country Link
US (2) US11643459B2 (cg-RX-API-DMAC7.html)
EP (2) EP3365368B1 (cg-RX-API-DMAC7.html)
JP (4) JP2019509737A (cg-RX-API-DMAC7.html)
KR (3) KR20250011248A (cg-RX-API-DMAC7.html)
CN (1) CN109071646A (cg-RX-API-DMAC7.html)
AU (2) AU2017230103A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018068340A2 (cg-RX-API-DMAC7.html)
CA (1) CA3055555A1 (cg-RX-API-DMAC7.html)
DK (1) DK3365368T3 (cg-RX-API-DMAC7.html)
EA (1) EA201891909A1 (cg-RX-API-DMAC7.html)
ES (1) ES2951648T3 (cg-RX-API-DMAC7.html)
FI (1) FI3365368T3 (cg-RX-API-DMAC7.html)
HU (1) HUE062976T2 (cg-RX-API-DMAC7.html)
IL (2) IL307835A (cg-RX-API-DMAC7.html)
MX (2) MX2018010948A (cg-RX-API-DMAC7.html)
PL (1) PL3365368T3 (cg-RX-API-DMAC7.html)
PT (1) PT3365368T (cg-RX-API-DMAC7.html)
SG (1) SG11201807176XA (cg-RX-API-DMAC7.html)
WO (1) WO2017156500A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022028680A (ja) * 2016-03-11 2022-02-16 スカラー ロック インコーポレイテッド ＴＧＦβ１結合性免疫グロブリンおよびその使用
JP2023510793A (ja) * 2020-01-11 2023-03-15 スカラー ロック インコーポレイテッド ＴＧＦβ阻害剤およびその使用
JP2023511255A (ja) * 2020-01-11 2023-03-17 スカラー ロック インコーポレイテッド ＴＧＦ－β阻害剤及びその使用

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102577551B1 (ko) * 2016-07-14 2023-09-11 스칼러 락, 인크. TGFβ 항체, 방법 및 용도
CN117398457A (zh) 2017-01-06 2024-01-16 供石公司 亚型特异性、背景许可性TGFβ1抑制剂及其用途
EP3600322A1 (en) * 2017-03-28 2020-02-05 Boehringer Ingelheim International GmbH Nintedanib for use in methods for the treatment of muscular dystrophy
EP4286013A3 (en) 2017-05-09 2024-02-28 Scholar Rock, Inc. Lrrc33 inhibitors and use thereof
EP3658583A1 (en) * 2017-07-28 2020-06-03 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
JP7315566B2 (ja) * 2018-02-23 2023-07-26 中外製薬株式会社 種交差性抗潜在型ＴＧＦ－β１抗体および使用方法
US20210340238A1 (en) 2018-07-11 2021-11-04 Scholar Rock, Inc. TGFß1 INHIBITORS AND USE THEREOF
MA53125A (fr) 2018-07-11 2021-05-19 Scholar Rock Inc Inhibiteurs de tgf?1 sélectifs selon l'isoforme à affinité élevée
RS62914B1 (sr) 2018-07-11 2022-03-31 Scholar Rock Inc Izoform selektivni inhibitori tgfbeta1 i njihova upotreba
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof
CA3118186A1 (en) * 2018-11-05 2020-05-14 Ludwig Institute For Cancer Research Ltd Humanized and variant tgf-.beta.1 specific antibodies and methods and uses thereof
EA202192130A1 (ru) 2019-01-30 2021-12-28 Сколар Рок, Инк. Специфичные к ltbp-комплексу ингибиторы tgf и их применение
CA3135988C (en) * 2019-06-10 2024-11-19 Shandong Boan Biotechnology Co., Ltd. Bifunctional fusion protein against PD-L1 and TGFS and its use
KR102823692B1 (ko) 2019-08-28 2025-06-20 추가이 세이야쿠 가부시키가이샤 종교차성 항잠재형 TGF-β1 항체 및 사용 방법
EP4126919A1 (en) * 2020-03-24 2023-02-08 Bio-Techne Corporation Methods of using a tgf beta knockout cell line and compositions resulting therefrom
BR112023014319A2 (pt) * 2021-01-18 2023-09-26 Jiangxi Jemincare Group Co Ltd Anticorpo contra a proteína garp e aplicação do mesmo
WO2022180764A1 (en) 2021-02-26 2022-09-01 Chugai Seiyaku Kabushiki Kaisha Uses of cross-species anti-latent tgf-beta 1 antibodies
JP7280400B2 (ja) * 2021-02-26 2023-05-23 中外製薬株式会社 種交差性抗潜在型ＴＧＦ－β１抗体の使用
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
CN117043187A (zh) * 2021-03-29 2023-11-10 山东先声生物制药有限公司 GARP/TGFβ1抗体及其应用
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
US20240301073A1 (en) 2021-07-14 2024-09-12 Scholar Rock, Inc. LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF
EP4499680A1 (en) 2022-03-29 2025-02-05 Allogene Therapeutics, Inc. Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
WO2024023283A1 (en) 2022-07-29 2024-02-01 Institut National de la Santé et de la Recherche Médicale Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
GB202219154D0 (en) * 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof
TW202434643A (zh) * 2023-01-09 2024-09-01 大陸商北京拓界生物醫藥科技有限公司 ＴＧＦβ１結合分子、ＧＡＲＰ－ＴＧＦβ１結合分子及其醫藥用途
EP4662245A1 (en) 2023-02-10 2025-12-17 Chugai Seiyaku Kabushiki Kaisha Anti-latent tgf-beta 1 antibodies and methods of use
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer
CN120131938B (zh) * 2025-03-19 2025-12-23 广州奥奇生物技术有限公司 一种益生菌制剂的制备方法及其在改善睡眠中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011102483A1 (ja) * 2010-02-19 2011-08-25 独立行政法人理化学研究所 ヒトTGF-βのLAPに結合する抗体
WO2013134365A1 (en) * 2012-03-08 2013-09-12 Ludwig Institute For Cancer Research Ltd TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
WO2014182676A2 (en) * 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2015015003A1 (en) * 2013-08-01 2015-02-05 Université Catholique de Louvain Anti-garp protein and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU1545692A (en) 1991-03-01 1992-10-06 Protein Engineering Corporation Process for the development of binding mini-proteins
US5658727A (en) 1991-04-10 1997-08-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
AU729406B2 (en) 1996-03-28 2001-02-01 Johns Hopkins University, The Soluble divalent and multivalent heterodimeric analogs of proteins
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
SK1152003A3 (en) 2000-06-29 2003-07-01 Abbott Lab Dual specificity antibodies and methods of making and using
GB0230202D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Ligand
JP4653660B2 (ja) 2003-09-04 2011-03-16 独立行政法人理化学研究所 ＴＧＦ−β活性化制御領域の切断面を認識する抗体
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
TR201901929T4 (tr) 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.
PL1874818T3 (pl) 2005-04-22 2011-09-30 Lilly Co Eli Przeciwciała swoiste wobec TGF-beta 1
JP5721951B2 (ja) 2007-03-22 2015-05-20 バイオジェン アイデック マサチューセッツ インコーポレイテッド 抗体、抗体誘導体、および抗体断片を含む、ｃｄ１５４に特異的に結合する結合タンパク質ならびにその使用
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
AU2009256246B2 (en) 2008-06-03 2013-07-18 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
JO3096B1 (ar) 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
BR112013020259A2 (pt) 2011-02-08 2018-05-15 Abbvie Inc tratamento de osteoartrite e dores
CA2837184C (en) 2011-05-25 2021-09-21 Innate Pharma, S.A. Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
MX351600B (es) 2011-06-03 2017-10-20 Xoma Technology Ltd Anticuerpo especificos para tgf-beta.
LT2718320T (lt) 2011-06-10 2018-04-10 Medimmune Limited Anti-pseodomonas psl surišančios molekulės ir jų panaudojimas
WO2013054307A2 (en) 2011-10-14 2013-04-18 Novartis Ag Antibodies and methods for wnt pathway-related diseases
AU2012335247A1 (en) 2011-11-08 2014-05-29 Pfizer Inc. Methods of treating inflammatory disorders using anti-M-CSF antibodies
US8871209B2 (en) 2011-11-14 2014-10-28 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A
CA3023553A1 (en) 2012-11-06 2014-05-15 Scholar Rock, Inc. Compositions and methods for modulating cell signaling
EP2968548B1 (en) 2013-03-15 2020-09-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
EP2832747A1 (en) 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
EP3139957A4 (en) 2014-05-06 2018-04-25 Scholar Rock, Inc. Compositions and methods for growth factor modulation
AU2015279212B2 (en) 2014-06-26 2020-08-20 Heidelberg Immunotherapeutics Gmbh Topical application for an anti-HSV antibody
WO2016079157A1 (en) 2014-11-18 2016-05-26 Institut Pasteur Polyclonal antibodies specific for serogroup x of n. meningitidis and uses thereof in diagnosis
SG10201906471PA (en) 2015-01-14 2019-09-27 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
TWI733661B (zh) * 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
DK3365368T3 (da) * 2016-03-11 2023-06-26 Scholar Rock Inc Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
KR102577551B1 (ko) 2016-07-14 2023-09-11 스칼러 락, 인크. TGFβ 항체, 방법 및 용도
CN117398457A (zh) 2017-01-06 2024-01-16 供石公司 亚型特异性、背景许可性TGFβ1抑制剂及其用途
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011102483A1 (ja) * 2010-02-19 2011-08-25 独立行政法人理化学研究所 ヒトTGF-βのLAPに結合する抗体
WO2013134365A1 (en) * 2012-03-08 2013-09-12 Ludwig Institute For Cancer Research Ltd TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
WO2014182676A2 (en) * 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2015015003A1 (en) * 2013-08-01 2015-02-05 Université Catholique de Louvain Anti-garp protein and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022028680A (ja) * 2016-03-11 2022-02-16 スカラー ロック インコーポレイテッド ＴＧＦβ１結合性免疫グロブリンおよびその使用
JP2023510793A (ja) * 2020-01-11 2023-03-15 スカラー ロック インコーポレイテッド ＴＧＦβ阻害剤およびその使用
JP2023511255A (ja) * 2020-01-11 2023-03-17 スカラー ロック インコーポレイテッド ＴＧＦ－β阻害剤及びその使用
JP7719779B2 (ja) 2020-01-11 2025-08-06 スカラー ロック インコーポレイテッド ＴＧＦβ阻害剤およびその使用

Also Published As

Publication number Publication date
DK3365368T3 (da) 2023-06-26
KR20180122397A (ko) 2018-11-12
JP2023108057A (ja) 2023-08-03
EP3365368A1 (en) 2018-08-29
EA201891909A1 (ru) 2019-02-28
HUE062976T2 (hu) 2023-12-28
EP3365368B1 (en) 2023-05-17
US20230348583A1 (en) 2023-11-02
KR20250011248A (ko) 2025-01-21
CA3055555A1 (en) 2017-09-14
IL261442A (en) 2018-10-31
IL307835A (en) 2023-12-01
CN109071646A (zh) 2018-12-21
US20190071493A1 (en) 2019-03-07
AU2017230103A1 (en) 2018-09-06
AU2024202692A1 (en) 2024-05-30
PL3365368T3 (pl) 2023-08-21
JP2022028680A (ja) 2022-02-16
BR112018068340A2 (pt) 2019-01-15
SG11201807176XA (en) 2018-09-27
MX2024005811A (es) 2024-05-28
KR20230088508A (ko) 2023-06-19
FI3365368T3 (fi) 2023-06-13
WO2017156500A8 (en) 2018-01-25
WO2017156500A9 (en) 2018-02-22
US11643459B2 (en) 2023-05-09
WO2017156500A1 (en) 2017-09-14
JP2022031403A (ja) 2022-02-18
ES2951648T3 (es) 2023-10-24
MX2018010948A (es) 2019-06-20
PT3365368T (pt) 2023-08-17
EP4169942A1 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
US20230348583A1 (en) TGFbeta1-BINDING IMMUNOGLOBULINS AND USE THEREOF
US20240016928A1 (en) Isoform-specific, context-permissive tgfb1 inhibitors and use thereof
US12358992B2 (en) LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof
US20240301073A1 (en) LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF
HK40089584A (en) Tgfbeta1-binding immunoglobulins and use thereof
HK1260186A1 (en) Tgfbeta1-binding immunoglobulins and use thereof
HK1260186B (en) Tgfbeta1-binding immunoglobulins and use thereof
EA048751B1 (ru) TGFβ1-СВЯЗЫВАЮЩИЕ ИММУНОГЛОБУЛИНЫ И ИХ ПРИМЕНЕНИЕ
BR122024003721A2 (pt) IMUNOGLOBULINAS DE LIGAÇÃO AO TGFbeta1 E USOS DESTAS
EA045239B1 (ru) СПЕЦИФИЧНЫЕ К ИЗОФОРМЕ, ПЕРМИССИВНЫЕ ПО ОТНОШЕНИЮ К КОНТЕКСТУ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210623

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211223

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211223

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220106

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220107

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220128

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220201

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20220203